FranceFrance

France Biotech calls for stimulus plan

25.02.2009

France’s biotech industry association has called on the country’s government to revise its decision to cut the OSEO budget by 50% (EUR320m). The tax-paid innovation agency supports small and medium-sized companies. In spite of French President Nicolas Sarkozy's reassurances on January 22nd, the French government has halved its support for innovative start-up companies for 2009. France Biotech argued that the industry currently already has access to too little funding. According to the organisation, investments in French biotechs had already dropped nearly 80% between 2007 and 2008 (down from EUR694m to EUR143m) In addition, says the association, venture capital investments in private companies fell by 27% to EUR132m.
France Biotech Chairman Philippe Pouletty said that "in order to underpin the optimism of our entrepreneurs, we must adopt an aggressive stimulus plan for young, innovative companies." Pouletty has therefore asked the government to reverse the decision and return OSEO’s funding to last year's level, and says that amount should be tripled in 2010. The association has also called on the government to extend the fiscal status of so-called "young innovative companies". Currently, research-oriented SMEs get tax exemptions for the first 8 years after being founded. France Biotech wants to extend that period to 15 years. The organisation also asked for a reform of the French credit law in order to distribute research tax credits more equitably between SMEs and multinationals, and wants 50% of the government's Strategic Investment Fund (FSI) to be given to innovative French SMEs to enable them to acquire undervalued foreign companies and technologies.

FranceFrance

28.03.2012

Minneapolis/Banzancourt – Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale. The French/US enterprise has now scaled up its...

FranceFrance

14.03.2012

Sophia Antipolis/ Madison – French NicOx S.A. and the global eye health specialist Bausch & Lomb have announced positive top-line results from their phase 2b dose finding study with BOL-303259-X, a nitric oxide-donating version...

FranceFrance

13.03.2012

Paris/Barcelona – French pharma company Sanofi strengthens its ties with the Spanish research institution CGR (Center for Genomic Regulation) in Barcelona. CGR stated on 12 March that the two partners agreed upon three years of...

FranceFrance

06.03.2012

Lyon – The sale of 1.6 million shares brought in €25.3m for French Adocia SAS during its IPO on the Euronext Paris. The price of €15.88 values the diabetes specialist at €96.1m at the upper end of the bookbuilding range. Late...

FranceFrance

05.03.2012

Pointing to a new study on Syngenta’s GM maize Bt11, France’s Environment Ministry has asked the European Commission to suspend authorisation for the use of the MON810 maize sold by US agri­biotech giant Monsanto as well. The...

FranceFrance

27.02.2012

Cambridge - Genzyme will shut the doors at its Cambridge R&D site by the end of the year, with up to 60 employees expected to lose their jobs. The move is part of an ongoing global restructuring of R&D by Sanofi, who purchased...

FranceFrance

07.02.2012

Lille – Shares of the French diabetes specialist Genfit S.A. almost doubled when the company published results of its Phase II study with the PPAR alpha and delta modulator GFT505. The compound has met the co-primary and...

FranceFrance

06.02.2012

Shares of the French diabetes specialist almost doubled when the companypublished results of its Phase II study with the PPAR alpha and deltamodulator GFT505. The compound has met the co-primary and secondaryendpoints while...

FranceFrance

02.02.2012

Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an...

FranceFrance

12.01.2012

Berlin/Paris – Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal, the vaccines division of the French drugmaker will gain exclusive access to a modified strain of...

Displaying results 1 to 10 out of 268

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-france/article/france-biotech-calls-for-stimulus-plan.html

Product of the week

Products

Events

All Events

Current issue

All issues